These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17463029)

  • 41. ExactFDR: exact computation of false discovery rate estimate in case-control association studies.
    Wojcik J; Forner K
    Bioinformatics; 2008 Oct; 24(20):2407-8. PubMed ID: 18662924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Planned missing data designs in psychological research.
    Graham JW; Taylor BJ; Olchowski AE; Cumsille PE
    Psychol Methods; 2006 Dec; 11(4):323-43. PubMed ID: 17154750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple testing to establish superiority/equivalence of a new treatment compared with k standard treatments for unbalanced designs.
    Kwong KS; Cheung SH; Chan WS
    Biometrics; 2004 Jun; 60(2):491-8. PubMed ID: 15180675
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimal design of experiments with anticipated pattern of missing observations.
    Imhof LA; Song D; Wong WK
    J Theor Biol; 2004 May; 228(2):251-60. PubMed ID: 15094019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Two-stage designs for the logistic regression model in single-agent bioassays.
    Myers WR; Myers RH; Carter WH; White KL
    J Biopharm Stat; 1996 Jul; 6(3):283-301. PubMed ID: 8854233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A generalized Sidak-Holm procedure and control of generalized error rates under independence.
    Guo W; Romano J
    Stat Appl Genet Mol Biol; 2007; 6():Article3. PubMed ID: 17402918
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Some optimal matrix designs in stability studies.
    DeWoody K; Raghavarao D
    J Biopharm Stat; 1997 May; 7(2):205-13. PubMed ID: 9136064
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimum two-stage designs in case-control association studies using false discovery rate.
    Kuchiba A; Tanaka NY; Ohashi Y
    J Hum Genet; 2006; 51(12):1046-1054. PubMed ID: 17003959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sample size calculations for designing clinical proteomic profiling studies using mass spectrometry.
    Nyangoma SO; Collins SI; Altman DG; Johnson P; Billingham LJ
    Stat Appl Genet Mol Biol; 2012 Feb; 11(3):Article 2. PubMed ID: 22499705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Sequential Rejection Testing Method for High-Dimensional Regression with Correlated Variables.
    Mandozzi J; Bühlmann P
    Int J Biostat; 2016 May; 12(1):79-95. PubMed ID: 27227719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combining adaptive designs with control of the false discovery rate--a generalized definition for a global p-value.
    Victor A; Hommel G
    Biom J; 2007 Feb; 49(1):94-106. PubMed ID: 17342952
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Robin Hood: A cost-efficient two-stage approach to large-scale simultaneous inference with non-homogeneous sparse effects.
    Pecanka J; Goeman J
    Stat Appl Genet Mol Biol; 2017 Apr; 16(2):107-132. PubMed ID: 28599402
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A two-stage hidden Markov model design for biomarker detection, with application to microbiome research.
    Zhou YH; Brooks P; Wang X
    Stat Biosci; 2018 Apr; 10(1):41-58. PubMed ID: 30174757
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.
    Bauer P; Bretz F; Dragalin V; König F; Wassmer G
    Stat Med; 2016 Feb; 35(3):325-47. PubMed ID: 25778935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biomarker discovery for heterogeneous diseases.
    Wallstrom G; Anderson KS; LaBaer J
    Cancer Epidemiol Biomarkers Prev; 2013 May; 22(5):747-55. PubMed ID: 23462916
    [TBL] [Abstract][Full Text] [Related]  

  • 56. False discovery rate control in two-stage designs.
    Zehetmayer S; Posch M
    BMC Bioinformatics; 2012 May; 13():81. PubMed ID: 22559038
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Robust joint analysis allowing for model uncertainty in two-stage genetic association studies.
    Pan D; Li Q; Jiang N; Liu A; Yu K
    BMC Bioinformatics; 2011 Jan; 12():9. PubMed ID: 21211060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two-stage designs applying methods differing in costs.
    Goll A; Bauer P
    Bioinformatics; 2007 Jun; 23(12):1519-26. PubMed ID: 17463029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimized multi-stage designs controlling the false discovery or the family-wise error rate.
    Zehetmayer S; Bauer P; Posch M
    Stat Med; 2008 Sep; 27(21):4145-60. PubMed ID: 18444249
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.